Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Follow-up care after treatment of ovarian and fallopian tube cancer

  • During the first two years, follow-up visits are every three months.
  • From the third until and including the fifth year, follow-up visits are every six months.
  • After five years, follow-up visits are annual.

Examinations:

  • Physical and clinical examinations. Routine testing of CA 125 and possibly other tumor markers is controversial.
  • Work-up with imaging or endoscopy is performed as needed.
  • Recurrence should be verified histologically or cytologically before new treatment is started. 

Follow-up of non-epithelial ovarian cancer

For non-epithelial ovarian cancer, most recurrences are diagnosed within 1-2 years, however granulosa cell tumors may recur later.

Examinations:

  • Gynecological examination and measurement of tumor markers (s-AFP, hCG, CA 125)
  • For virilizing tumor, s-testosterone is a tumor marker. 

s-CA 125

Measurement of s-CA125 is normally not used in follow-up. There may be incidental variations of +/- 70 %, without having any significance. Gynecologic Cancer Intergroup (GCIG) has agreed that an increase of at least 100% must be present to define progression. From a normal value there must be an increase of 70 IU or more before the increase is diagnostic.  

If there is a positive increase of s-CA 125, but the gynecological examination, chest X-ray, and CT of the abdomen/pelvis do not show sign of recurrence, an MRI or PET scan will confirm a tumor, if present. 

It has long been discussed whether treatment of early recurrence based on CA125 gives better survival than treatment started after clinical detection of recurrence. Results from a randomized prospective study (ICON5) have recently been published showing not difference between the groups, and these results may influence follow-up recommendations.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017